Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer
作者： Ji-Yeon Kim , Eun Shin , Jin Won Kim , Hye Seung Lee , Dae-Won Lee
DOI: 10.1371/JOURNAL.PONE.0120324
关键词: Lymph node 、 Cancer 、 Reverse transcription polymerase chain reaction 、 Thymidylate synthase 、 Thymidine phosphorylase 、 Chemotherapy 、 Pathology 、 Dihydropyrimidine dehydrogenase 、 Internal medicine 、 Oncology 、 Tegafur 、 Medicine
摘要: We analyzed the expression levels of fluoropyrimidine-metabolizing enzymes (thymidylate synthase [TS], dihydropyrimidine dehydrogenase [DPD], thymidine phosphorylase [TP] and orotate phosphoribosyltransferase [OPRT]) to identify potential biomarkers related treatment outcomes in gastric cancer (GC) patients receiving adjuvant S-1 chemotherapy. In this study, 184 who received curative gastrectomy (D2 lymph node dissection) were included. Immunohistochemistry quantitative reverse transcription polymerase chain reaction performed measure protein mRNA TS, DPD, TP, OPRT tumor tissue. univariate analysis, low intratumoral DPD was poorer 5-year disease-free survival (DFS; 78% vs. 88%; P = 0.068). Low (1st [lowest] quartile) also DFS (69% 90%; < 0.001) compared high (2nd 4th quartiles). multivariate analyses, or worse (P 0.05), irrespective other clinical variables. not outcomes. Severe non-hematologic toxicities (grade ≥ 3) had a trend towards more frequent development with (29% 16%; conclusion, GC did have inferior outcome following therapy those expression. Instead, poor DFS.
paperity.org
core.ac.uk 参考文章(33)
In Sil Choi, Hye Seung Lee, Keun-Wook Lee, Haeryoung Kim, Ki Hwan Kim, Yu Jung Kim, Jee Hyun Kim, Woo Ho Kim, Jong Seok Lee, Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes Medical Oncology. ,vol. 28, pp. 991- 998 ,(2011) , 10.1007/S12032-010-9590-4
S Miyamoto, N Boku, A Ohtsu, S Yoshida, A Ochiai, H Okabe, M Fukushima, Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. International Journal of Oncology. ,vol. 17, pp. 653- 661 ,(2000) , 10.3892/IJO.17.4.653
Mitsuru Sasako, Shinichi Sakuramoto, Hitoshi Katai, Taira Kinoshita, Hiroshi Furukawa, Toshiharu Yamaguchi, Atsushi Nashimoto, Masashi Fujii, Toshifusa Nakajima, Yasuo Ohashi, None, Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer Journal of Clinical Oncology. ,vol. 29, pp. 4387- 4393 ,(2011) , 10.1200/JCO.2011.36.5908
Yung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, Hyun Cheol Chung, Young-Kyu Park, Kyung Hee Lee, Keun-Wook Lee, Yong Ho Kim, Sang-Ik Noh, Jae Yong Cho, Young Jae Mok, Yeul Hong Kim, Jiafu Ji, Ta-Sen Yeh, Peter Button, Florin Sirzén, Sung Hoon Noh, Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial The Lancet. ,vol. 379, pp. 315- 321 ,(2012) , 10.1016/S0140-6736(11)61873-4
Yoshihide Otani, Koichiro Kumai, Teiji Takechi, Masaki Kitajima, Yoichiro Ishikawa, Tatsuo Teramoto, Tetsuro Kubota, Masakazu Fukushima, Masahiko Watanabe, Hiroyuki Okabe, Dihydropyrimidine Dehydrogenase Activity and Messenger RNA Level May Be Related to the Antitumor Effect of 5-Fluorouracil on Human Tumor Xenografts in Nude Mice Clinical Cancer Research. ,vol. 5, pp. 883- 889 ,(1999)
N. Kim, C. Park, D.J. Park, H.-H. Kim, S. Kim, Y.J. Kim, J.H. Kim, J.S. Lee, Y.-J. Bang, S.I. Khwarg, H. Choung, M.J. Lee, K.-W. Lee, Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy Annals of Oncology. ,vol. 23, pp. 2065- 2071 ,(2012) , 10.1093/ANNONC/MDS106
Hei-Cheul Jeung, Sun Young Rha, Sang Joon Shin, Seung Joon Lim, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung, Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer Anti-Cancer Drugs. ,vol. 22, pp. 801- 810 ,(2011) , 10.1097/CAD.0B013E328345C9AE
Ken-Ichi Katsu, Hiroya Takiuchi, Shin-Ichiro Kawabe, Masahiro Gotoh, Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointestinal cancer research : GCR. ,vol. 1, pp. 171- 176 ,(2007)
Koichiro Kumai, Yoshiro Saikawa, Masashi Yoshida, Tetsuro Kubota, Masahiko Watanabe, Fumiki Toriumi, Yoshihide Otani, Masaki Kitajima, Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Research. ,vol. 24, pp. 2455- 2463 ,(2004)
Yasuhide Yamada, Masahiro Fukuoka, Hisateru Yasui, Toshio Shimizu, Kuniaki Shirao, Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer Research. ,vol. 25, pp. 2997- 3001 ,(2005)